6 completed, 3 terminated, 1 active not recruiting, 1 unknown. 11 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 6, Terminated 3, Active not recruiting 1, Unknown 1 |
| Phase 1 | 4 | Completed 2, Terminated 1, Unknown 1 |
Follow glasdegib: new trials by email Literature Review of glasdegib trials Research Report on glasdegib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia Glasdegib, CPX-351 - Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 2 | Active not recruiting | University of California, Irvine | 30 | 2020-02-19 | 2026-07-16 |
| GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia Glasdegib, Decitabine - ACUTE MYELOID LEUKEMIA | Phase 2 | Terminated | Yale University | 1 | 2019-12-06 | 2021-10-15 |
| Glasdegib for Chronic Graft-Versus-Host Disease Glasdegib - Chronic Graft Versus Host Disease, Fasciitis | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 15 | 2019-12-03 | 2024-10-29 |
| Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma PF-04449913, Temozolomide Oral Capsule - Glioblastoma | Phase 1 / Phase 2 | Completed | Grupo Español de Investigación en Neurooncología | 75 | 2018-03-15 | 2024-03-28 |
| Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease Glasdegib - Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder) | Phase 1 / Phase 2 | Unknown | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | 21 | 2018-01-09 | 2022-03-17 |
| OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia Anti-OX40 Agonist Monoclonal Antibody PF-04518600, Avelumab, Azacitidine - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 50 | 2017-12-27 | 2023-09-05 |
| Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia Cytarabine, Decitabine, Idarubicin - Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 2 | Completed | University of Nebraska | 75 | 2017-07-07 | 2026-03-10 |
| Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib Glasdegib (PF-04449913), Placebo - Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Terminated | Pfizer | 21 | 2014-10-06 | 2019-01-17 |
| Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) PF-04449913 - Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML) | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 35 | 2013-08-29 | 2021-06-14 |
| PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant PF-04449913 - Adult Acute Myeloid Leukemia in Remission, Recurrent Adult Acute Myeloid Leukemia | Phase 2 | Completed | University of Colorado, Denver | 31 | 2013-04-29 | 2022-01-25 |
| A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome PF-04449913, Low dose ARA-C (LDAC), Decitabine - Acute Myeloid Leukemia | Phase 2 | Completed | Pfizer | 255 | 2012-06-27 | 2020-03-03 |
Leukemia, Myeloid, Acute (6) · Myelodysplastic Syndromes (2) · Bronchiolitis Obliterans Syndrome (1) · Fasciitis (1) · Glioblastoma (1) · Graft vs Host Disease (1) · Leukemia (1) · Leukemia, Myeloid (1) · Leukemia, Myelomonocytic, Chronic (1) · Primary Myelofibrosis (1)
Pfizer (2) · Fred Hutchinson Cancer Center (1) · Grupo Espanol de trasplantes hematopoyeticos y terapia celular (1) · Grupo Español de Investigación en Neurooncología (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · University of California, Irvine (1) · University of Colorado, Denver (1) · University of Nebraska (1) · Yale University (1)
United States (9) · Spain (3) · Canada (1) · Germany (1) · Italy (1) · Japan (1) · Poland (1)
Amer M Zeidan, MBBS (1) · Daniel A Pollyea, MD, MS (1) · Deepa Jeyakumar, MD (1) · Jeffrey Lancet, M.D. (1) · Naval G Daver (1) · Stephanie Lee (1) · Vijaya R Bhatt, MD (1)
PMID 37698881, PMID 29463550, PMID 30074259, PMID 30555165, PMID 32664995, PMID 32885274, PMID 33740113, PMID 35442137, PMID 35450817, PMID 38000343, PMID 40298352
2017 (2), 2014 (1), P30CA036727 (1)